Neil Bhowmick

List of Publications by Year in Descending Order

119 papers	9,998 citations	43 h-index	99 g-index
145 ext. papers	10,945 ext. citations	6.5 avg, IF	6.03 L-index

#	Paper	IF	Citations
119	Plasma metabolomics to predict chemotherapy (CTX) response in advanced pancreatic cancer (PC) patients (pts) on enteral feeding for cachexia.. *Journal of Clinical Oncology*, **2022**, 40, 600-600	2.2	0
118	A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).. *Journal of Clinical Oncology*, **2022**, 40, TPS636-TPS636	2.2	
117	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2022**, 40, 12.e13-12.e22	2.8	1
116	Functional Diversity of Macropinocytosis.. *Sub-Cellular Biochemistry*, **2022**, 98, 3-14	5.5	
115	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. *Drugs*, **2022**, 82, 439	12.1	0
114	Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer. *Cancers*, **2022**, 14, 2491	6.6	1
113	A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth. *Molecular Therapy*, **2021**,	11.7	3
112	Bone marrow mesenchymal stem cells interact with head and neck squamous cell carcinoma cells to promote cancer progression and drug resistance. *Neoplasia*, **2021**, 23, 118-128	6.4	4
111	A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARG, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma. *Cancer Research*, **2021**, 81, 1216-1229	10.1	8
110	Deregulated 14-3-3□and methionine adenosyltransferase 1□ interplay promotes liver cancer tumorigenesis in mice and humans. *Oncogene*, **2021**, 40, 5866-5879	9.2	0
109	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. *OncoTargets and Therapy*, **2021**, 14, 4819-4832	4.4	4
108	Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification. *Oncology*, **2021**, 35, 528-535	1.8	
107	Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. *Clinical Genitourinary Cancer*, **2020**, 18, 425-428	3.3	5
106	Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. *Anticancer Research*, **2020**, 40, 1459-1462	2.3	6
105	Soluble CD105 is prognostic of disease recurrence in prostate cancer patients. *Endocrine-Related Cancer*, **2020**, 27, 1-9	5.7	6
104	COVID-19 and androgen-targeted therapy for prostate cancer patients. *Endocrine-Related Cancer*, **2020**, 27, R281-R292	5.7	36
103	Deconstructing tumor heterogeneity: the stromal perspective. *Oncotarget*, **2020**, 11, 3621-3632	3.3	12

102	Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells. *Oncogene*, **2020**, 39, 1543-1556	9.2	28
101	Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. *Cancers*, **2020**, 12,	6.6	5
100	The adaptor protein SHCA launches cancer invasion. *Journal of Biological Chemistry*, **2020**, 295, 10560-10561	5.4	0
99	Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 8515-8523	11.5	4
98	Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma. *Case Reports in Urology*, **2019**, 2019, 6769017	0.5	9
97	NOD-like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD. *Hepatology*, **2019**, 70, 1582-1599	11.2	31
96	In Reply. *Stem Cells Translational Medicine*, **2019**, 8, 739-740	6.9	1
95	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. *Stem Cells Translational Medicine*, **2019**, 8, 441-449	6.9	33
94	Epigenetic changes in fibroblasts drive cancer metabolism and differentiation. *Endocrine-Related Cancer*, **2019**, 26, R673-R688	5.7	27
93	Visualization of Macropinocytosis in Prostate Fibroblasts. *Bio-protocol*, **2019**, 9,	0.9	4
92	3D Co-culture System of Mouse Prostatic Wild-type Fibroblasts withHuman Prostate Cancer Epithelial Cells. *Bio-protocol*, **2019**, 9, e3225	0.9	
91	Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells. *Cancer Letters*, **2019**, 449, 145-162	9.9	8
90	ACTR-15. PHASE 1 TRIAL OF A KETOGENIC DIET IN PATIENTS RECEIVING STANDARD-OF-CARE TREATMENT FOR RECENTLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2019**, 21, vi15-vi15	1	0
89	Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. *Oncogene*, **2019**, 38, 716-730	9.2	37
88	Regulation of inside-out β1-integrin activation by CDCP1. *Oncogene*, **2018**, 37, 2817-2836	9.2	14
87	Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. *Journal of Medicinal Chemistry*, **2018**, 61, 2052-2061	8.3	32
86	Antagonizing CD105 enhances radiation sensitivity in prostate cancer. *Oncogene*, **2018**, 37, 4385-4397	9.2	15
85	Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. *Cancer Medicine*, **2018**, 7, 4639-4649	4.8	9

84	Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. *Journal of Clinical Investigation*, **2018**, 128, 4472-4484	15.9	69
83	An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. *Gastroenterology*, **2018**, 155, 1985-1998.e5	13.3	33
82	Notch inhibitor screening reveals an unexpected HES1 heterodimer. *Journal of Biological Chemistry*, **2018**, 293, 8295-8296	5.4	2
81	MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. *Cancer Research*, **2017**, 77, 2306-2317	10.1	89
80	Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. *Cancer Research*, **2017**, 77, 1331-1344	10.1	38
79	Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. *Endocrinology*, **2017**, 158, 2255-2268	4.8	14
78	FOXC1: an emerging marker and therapeutic target for cancer. *Oncogene*, **2017**, 36, 3957-3963	9.2	64
77	MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. *Endocrine-Related Cancer*, **2017**, 24, R157-R172	5.7	49
76	S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis. *Oncotarget*, **2017**, 8, 78851-78869	3.3	21
75	-Derived Lipopolysaccharide Combines Hypoxia to Induce Caspase-1 Activation in Periodontitis. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 474	5.9	34
74	Modulation of cabozantinib efficacy by the prostate tumor microenvironment. *Oncotarget*, **2017**, 8, 87891-87902	5.3	12
73	Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases.. *Journal of Clinical Oncology*, **2017**, 35, 5031-5031	2.2	
72	Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis. *Oncogene*, **2016**, 35, 2370-8	9.2	36
71	Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations. *Molecular Cancer Research*, **2016**, 14, 374-84	6.6	25
70	A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. *Biomaterials*, **2016**, 91, 140-150	15.6	55
69	A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. *Journal of Clinical Oncology*, **2016**, 34, 208-208	2.2	1
68	A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. *Journal of Clinical Oncology*, **2016**, 34, e16552-e16552	2.2	
67	Role of EMT in Metastasis and Therapy Resistance. *Journal of Clinical Medicine*, **2016**, 5,	5.1	294

66	Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. *Scientific Reports*, **2016**, 6, 39257	4.9	11
65	A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer. *Phytotherapy Research*, **2015**, 29, 805-17	6.7	56
64	Inflammation and pyroptosis mediate muscle expansion in an interleukin-1 (IL-1)-dependent manner. *Journal of Biological Chemistry*, **2015**, 290, 6574-83	5.4	34
63	SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. *Oncotarget*, **2015**, 6, 44072-83	3.3	19
62	A reciprocal role of prostate cancer on stromal DNA damage. *Oncogene*, **2014**, 33, 4924-31	9.2	31
61	Mechanisms of hemorrhagic cystitis. *American Journal of Clinical and Experimental Urology*, **2014**, 2, 199-208	2.8	30
60	A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.. *Journal of Clinical Oncology*, **2014**, 32, e16080-e16080	2.2	
59	The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. *Cancer Cell*, **2013**, 23, 332-46	24.3	107
58	Targeted delivery of paclitaxel to EphA2-expressing cancer cells. *Clinical Cancer Research*, **2013**, 19, 128-37	7.9	45
57	Large oncosomes mediate intercellular transfer of functional microRNA. *Cell Cycle*, **2013**, 12, 3526-36	4.7	157
56	A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. *PLoS ONE*, **2013**, 8, e54918	3.7	49
55	Metastatic ability: adapting to a tissue site unseen. *Cancer Cell*, **2012**, 22, 563-4	24.3	5
54	Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. *Neoplasia*, **2012**, 14, 656-65	6.4	36
53	Understanding the role of stromal fibroblasts in cancer progression. *Cell Adhesion and Migration*, **2012**, 6, 231-5	3.2	73
52	Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. *American Journal of Pathology*, **2012**, 181, 1573-84	5.8	249
51	Loss of epithelial oestrogen receptor inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models. *Journal of Pathology*, **2012**, 226, 17-27	9.4	28
50	Loss of TGF- responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. *Molecular Cancer Research*, **2012**, 10, 494-503	6.6	54
49	Modeling Transforming Growth Factor- Signaling in Cancer **2012**, 397-415		

48	Mesenchymal stem cell recruitment and improved bladder function after bladder outlet obstruction: preliminary data. *Journal of Urology*, **2011**, 185, 1132-8	2.5	52
47	Serum methionine metabolites are risk factors for metastatic prostate cancer progression. *PLoS ONE*, **2011**, 6, e22486	3.7	66
46	Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. *Oncogene*, **2011**, 30, 167-77	9.2	33
45	Altered TGF- signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. *Cancer Research*, **2011**, 71, 1272-81	10.1	137
44	Role for stromal heterogeneity in prostate tumorigenesis. *Cancer Research*, **2011**, 71, 3459-70	10.1	70
43	Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. *PLoS ONE*, **2011**, 6, e27529	3.7	57
42	Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. *PLoS ONE*, **2010**, 5, e12920	3.7	44
41	Could stroma contribute to field cancerization?. *Medical Hypotheses*, **2010**, 75, 26-31	3.8	28
40	Dermal transforming growth factor-beta responsiveness mediates wound contraction and epithelial closure. *American Journal of Pathology*, **2010**, 176, 98-107	5.8	73
39	Autoimmune pancreatitis results from loss of TGFbeta signalling in S100A4-positive dendritic cells. *Gut*, **2009**, 58, 1267-74	19.2	43
38	Identification of extracellular delta-catenin accumulation for prostate cancer detection. *Prostate*, **2009**, 69, 411-8	4.2	87
37	Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. *Differentiation*, **2009**, 77, 95-102	3.5	35
36	Bladder stromal loss of transforming growth factor receptor II decreases fibrosis after bladder obstruction. *Journal of Urology*, **2009**, 182, 1775-80	2.5	22
35	Recruitment of bone marrow derived cells to the bladder after bladder outlet obstruction. *Journal of Urology*, **2009**, 182, 1769-74	2.5	26
34	Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. *Oncogene*, **2008**, 27, 7118-30	9.2	125
33	Gene targeting to the stroma of the prostate and bone. *Differentiation*, **2008**, 76, 606-23	3.5	12
32	Nicotinic signaling ameliorates acute bladder inflammation induced by protamine sulfate or cyclophosphamide. *Journal of Urology*, **2008**, 179, 2440-6	2.5	14
31	Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. *American Journal of Pathology*, **2008**, 172, 59-67	5.8	22

30	Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. *Journal of Urology*, **2008**, 180, 1784-9	2.5	25
29	Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. *Journal of Urology*, **2008**, 180, 1778-83	2.5	60
28	Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. *Clinical Cancer Research*, **2008**, 14, 7790-7	12.9	45
27	Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. *Cancer Research*, **2008**, 68, 4709-18	10.1	93
26	The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. *Cancer Research*, **2008**, 68, 6762-9	10.1	149
25	Transforming growth factor-beta (TGF-beta) and TGF-beta-associated kinase 1 are required for R-Ras-mediated transformation of mammary epithelial cells. *Cancer Research*, **2008**, 68, 6224-31	10.1	14
24	TGF-Signaling in Fibroblastic Cells and Oncogenesis **2008**, 185-198		1
23	Signaling pathways regulating TC21-induced tumorigenesis. *Journal of Biological Chemistry*, **2007**, 282, 27713-20	5.4	28
22	Directed differentiation of embryonic stem cells into bladder tissue. *Developmental Biology*, **2007**, 304, 556-66	3.1	83
21	Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. *Biochemical and Biophysical Research Communications*, **2007**, 353, 829-34	3.4	85
20	Urothelial inhibition of transforming growth factor-beta in a bladder tissue recombination model. *Journal of Urology*, **2007**, 178, 1643-9	2.5	3
19	Bladder tissue formation from cultured bladder urothelium. *Developmental Dynamics*, **2006**, 235, 2795-801	2.9	19
18	Essential role of Smad3 in angiotensin II-induced vascular fibrosis. *Circulation Research*, **2006**, 98, 1032-9	15.7	185
17	Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. *Cancer Research*, **2006**, 66, 8007-16	10.1	95
16	Stromal hyperplasia in male bladders upon loss of transforming growth factor-beta signaling in fibroblasts. *Journal of Urology*, **2005**, 174, 1704-7; discussion 1707	2.5	18
15	Tumor-stroma interactions. *Current Opinion in Genetics and Development*, **2005**, 15, 97-101	4.9	366
14	Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. *Oncogene*, **2005**, 24, 5053-68	9.2	236
13	Linking TGF-beta-mediated Cdc25A Inhibition and Cytoskeletal Tegulation through RhoA/p160ROCK Signaling. *Cell Cycle*, **2004**, 3, 406-408	4.7	7

12	Stromal fibroblasts in cancer initiation and progression. *Nature*, **2004**, 432, 332-7	50.4	1811
11	TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science*, **2004**, 303, 848-51	33.3	1141
10	TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 15548-53	11.5	105
9	The loss of TGF-beta signaling promotes prostate cancer metastasis. *Neoplasia*, **2003**, 5, 267-77	6.4	85
8	Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. *American Journal of Pathology*, **2003**, 163, 1539-49	5.8	113
7	Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. *Breast Cancer Research*, **2003**, 5, R187-98	8.3	105
6	Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. *Journal of Biological Chemistry*, **2001**, 276, 46707-13	5.4	316
5	Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. *Molecular Biology of the Cell*, **2001**, 12, 27-36	3.5	863
4	Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. *Journal of Biological Chemistry*, **2000**, 275, 36803-10	5.4	770
3	Surface retention of an inactivating lutropin receptor mutant in exoloop 3. *Molecular and Cellular Biochemistry*, **1998**, 187, 221-7	4.2	3
2	hCG-receptor binding and transmembrane signaling. *Molecular and Cellular Endocrinology*, **1996**, 125, 55-64	4.4	30
1	Identification of Ionizable Amino Acid Residues on the Extracellular Domain of the Lutropin Receptor Involved in Ligand Binding		10